A study has cast doubt on the widely cited claim that antidepressant drugs such as SSRIs have few withdrawal symptoms, revealing that pharmaceutical industry funding could be skewing data to minimise adverse effects. This story first appeared on leafie, view here Author: Liam O'Dowd
Cannabis Health will host its first expert-led educational event for healthcare professionals later this year, with a focus on bridging the gap between policy and patient access. The one-day, CPD-accredited Cannabis Health Symposium, taking place at Conway Hall in London on Tuesday 25 November, 2025, is [...]
Despite a slow start in facilitating patient access to medical cannabis treatments, this is gradually changing for the better. The UK now has an active patient base of approximately 50,000-60,000, and an estimated 80,000 individuals are expected to receive treatment with CBPMs throughout 2025. The CQC [...]
Copyright © 2020 – 2025 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.
